Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) 53.8% LOWER; announced top-line results from its U.S. Phase II clinical trial to treat cocaine addiction. The data from the trial showed that CPP-109 did not demonstrate statistical significance in the primary endpoint — that a significantly larger proportion of CPP-109-treated subjects than placebo-treated subjects were cocaine-free during the last two weeks of the treatment period (Weeks 11 and 12). The clinical trial did not reveal any unexpected “serious” adverse events.

Oculus Innovative Sciences (Nasdaq: OCLS) 24.6% LOWER; correcting today following a 310% rise over the last 2 trading days on news that